ArticleBMC medical research methodology2026
Summary measures derived from a multi-state modeling framework to characterize the course of heart disease.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe course of heart disease involves multiple endpoints, and how to characterize this course needs investigation. Multi-state models are commonly used to model the disease course, estimating state occupation probabilities (survival risks) in each state over time. These transition parameters are state- and time-specific, which makes the model difficult to use for characterization of the entire course and for comparative effectiveness of exposures.
methodsA Discrete-time Split-state Framework has been proposed, which splits disease states into substates conditioned on past disease history. This framework is “memoryless” in that the newly created substates are independent of past history, thereby relaxing the Markov assumption. It is also “memorable” because the substates contain information about past history. In this paper, we leverage the “memoryless” and “memorable” features of the framework to synthesize the estimated transition parameters into two summary measures: Multimorbidity-Adjusted Life Year (MALY), and disease path. MALY takes the multimorbidity of each substate into consideration and estimates the adjusted life years in full health. Disease path describes the progression of disease and elucidates disease mechanisms.
resultsIn the application, we characterized the course of heart disease using data from the Atherosclerosis Risk in Communities (ARIC) study. The disease course was modeled in five states: healthy, at metabolic risk, coronary heart disease (CHD), heart failure, and mortality. In this mid- to old-age population, the estimated MALY was 26.53 years (95% CI: 18.63, 34.77), and the corresponding multimorbidity-adjusted life expectancy was 80.92 years (95% CI: 79.30, 82.72). For healthy participants at baseline, the most likely paths were “Healthy → at metabolic risk → CVD mortality” (38%), “Healthy → non-CVD mortality” (23%), and “Healthy → at metabolic risk → heart failure → CVD mortality” (17%).
conclusionsIn summary, MALY and Disease Path characterize the course of heart disease and have potential use in precision prevention and prediction of heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.